BCDA

Business Context and Reporting Period

Company: Cardo Medical, Inc. (Note: Input metadata referenced "Biocardia," but the filing text identifies the registrant as Cardo Medical, Inc.)
Filing Type: Form 10-K Annual Report
Period Ended: December 31, 2009
Business Overview: Cardo is an orthopedic medical device company specializing in reconstructive joint devices (knee, hip) and spinal surgical devices. The company focuses on developing instrumentation to facilitate outpatient surgical procedures. Operations are divided into two segments: Reconstructive and Spine.

Key Financial Metrics

Segment Performance (2009): Reconstructive Division generated $1.54 million in sales; Spine Division generated $329,000 in sales.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 47% ($601,000) driven by wider acceptance of Hip and Spine products. Hip sales grew from $66,000 to $393,000, and Spine sales increased by $191,000.
• Gross Margin Compression: Gross margin decreased from 84.5% to 79.7%. This was primarily due to a shift in sales mix; high-margin knee products accounted for ~60% of sales in 2009 compared to over 85% in 2008.
• Expense Fluctuations:
  • R&D: Decreased 25% to $1.0 million, largely due to the absence of $938,000 in acquired in-process R&D expenses recorded in 2008.
  • SG&A: Increased 43% to $5.6 million due to fully staffed operations, increased depreciation/amortization ($1.2 million vs. $561,000), and higher payroll costs.
• Impairment: No impairment charges were recorded in 2009, compared to a $1.457 million goodwill impairment charge in 2008 related to the Cervical Xpand acquisition.
• Acquisitions: In late 2009, the company acquired substantially all assets of Vertebron, Inc. (spine inventory and IP) for $1.3 million.

Guidance, Outlook, and Risks

• Liquidity and Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern. With approximately $5.0 million in cash, funds are not projected to meet working capital needs for the next 12 months. The company anticipates sustaining losses through the first three quarters of 2010 and may require additional debt or equity financing.
• Capital Raising: In 2009, the company raised approximately $9.0 million net through private placements. Future financing is critical for operations and growth.
• Operational Outlook: The company plans to accelerate R&D, expand sales and marketing personnel, and increase inventory levels. It expects to release patient-specific instrumentation for knee systems in Q4 2010.
• Key Risks:
  • Customer Concentration: Three hospital customers comprised 64% of net sales in 2009.
  • Regulatory: Dependence on FDA 510(k) clearances; potential impact of healthcare reform legislation (e.g., 2.3% excise tax on devices starting 2013).
  • Competition: Highly competitive market dominated by larger firms (Zimmer, J&J, Stryker) with greater resources.
  • Stock Liquidity: Common stock trades on the OTC Bulletin Board and may be thinly traded.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $4.97 million cash balance against projected burn rates and the timeline for securing additional financing.
• Customer Concentration: Assess the risk associated with the top three customers representing 64% of revenue.
• Financing Terms: Review the terms of recent private placements (lock-up periods, warrant issuance) and potential dilution from future equity raises.
• Inventory Valuation: Confirm the realizability of the $3.26 million inventory balance, particularly the $1.3 million acquired from Vertebron.
• Internal Controls: Note that material weaknesses in internal controls identified in 2008 were remediated in Q4 2009; verify the stability of these new controls.